Blue Lake Biotechnology Inc., a startup company, developed a COVID vaccine that effectively reduces COVID symptoms. According to the results gathered from the phase I clinical trial, it gives protection for three months for people who take it as a booster dose.
86% more effective in reducing coronavirus
According to the latest news on health, the nasal vaccine developed by Blue Lake is 86% more effective in reducing the symptoms of coronavirus infections in people aged between 18 and 49 years. According to the CDCP (Centers for Disease Control and Prevention), it is more effective compared to other COVID vaccines on the market that are 43 percent effective in lowering coronavirus symptoms.
The nasal vaccine strengthens immunity
Most viruses enter the body through the nose. Scientists say nasal vaccines offer better protection against coronavirus compared to those injected into your arm. A nasal vaccine is sprayed into the nose to boost immunity and contain respiratory diseases. An assistant professor at the Yale School of Medicine, Dr. Benjamin Goldman-Israelow, said the main aim is to strengthen your immunity so that infection fails to cause any impact on your body. Dr. Benjamin is not involved in the phase 1 clinical trial of Blue Lake’s nasal vaccine.
Dr. Benjamin conducted his clinical trials in animals and observed improved protection against the deadly virus, according to an article published in a health magazine in October. He and his colleagues showed in the clinical study that the nasal vaccine induces a strong response in the upper airway of your nose. It has a better chance of containing coronavirus infections than those injected into the body.
The US’ progress in developing nasal vaccines is sluggish compared to other nations worldwide. Most nasal vaccines in the US are in preclinical studies. Apart from Blue Lake, other nasal vaccines developed by Mount Sinai researchers in New York City have only reached human trials.
India, Russia, and Iran approved the use of nasal COVID vaccines
A handful of nations, including Russia, India, and Iran, have approved the use of nasal COVID vaccines. An inhalable version of the vaccine is also used as a booster in some nations in September. However, few details about their efficacy are available.
Recruits 72 participants for the clinical trial
Blue Lake has recruited 72 people aged between 18 and 55 for the phase 1 clinical trial of its nasal COVID vaccine. It has included those who received two doses of the vaccine (mRNA) and others who have not received any vaccine in the clinical trial. The company commenced the clinical study in August 2021, and the scientists will continue to collect data from the patients until December.
In the latest world news, the data released in early February is preliminary, and more research is needed before drawing any conclusions. However, the vaccine is showing promising results according to the details available so far.
The CEO and founder of a Georgia-based startup, Athens, Biao claims that the nasal vaccine provides better protection for a longer time than the mRNA vaccine. He further went on to say that three more clinical trials of the nasal vaccine are needed to know more about its effectiveness. However, the nasal vaccine has shown impressive results in Phase 1 clinical trial.